Abstract
Overview
Introduction
The 2004 withdrawal of Vioxx from the global market had a negative effect on
the COX-2 class, with a 44% fall in Celebrex sales for osteoarthritis in 2005.
However, as patients sought an alternative to the COX-2s, there was positive
growth in traditional NSAIDs, non-narcotic analgesics, narcotic analgesics,
corticosteroids and HA viscosupplements, leading to a 1.1% increase in total
market value.
Scope
- Sales and volume forecasts for the leading osteoarthritis therapies to
2015, calculated for the osteoarthritis indication alone
- Assessment of current and future opportunities and threats in the
osteoarthritis market across the seven major pharmaceutical markets
- Key events that may affect revenues are applied and discussed for each of
the seven major pharmaceutical markets.
- Case studies outline future strategies companies will use for advertising
and marketing COX-2 inhibitors and the factors behind the success of Synvisc
Highlights
The osteoarthritis market is forecast to grow steadily, and will reach $7
billion by 2015. Growth comes from expanded use of hyaluronic acids and
pipeline products launches. Despite competition from COX-2s such as Prexige
and Arcoxia, Pfizer' s Celebrex to remain the leading brand until patent expiry
in 2014.
After the withdrawal of Vioxx over CV safety fears, Merck was criticized for
its heavy marketing campaign. Companies should target their products to
specific populations rather than the population as a whole, shift to eSampling
and continue to conduct large-scale safety studies.
Synvisc sales will reach $300 million by 2015. Indication expansions in the US
and EU, and launch in Japan, will drive sales. Future opportunities in the HA
market will come from the development of single injection products. The EU
markets show good opportunity for HAs with the highest growth.
Reasons to Purchase
- Assess the impact of events such as patent expiries and indication
expansion on the osteoarthritis sales of key brand name products
- Quantify the future size of the market, in terms of volume and value, for
the osteoarthritis indication in each of the seven major markets
- Understand strategies that pharmaceutical companies will use to market
COX-2s in the future
| 
View Cart
